Although recent evidence suggests that myeloid clonal hematopoiesis (M-CH) may influence lymphoma clinical outcome, its impact in mantle cell lymphoma (MCL) remains unclear. Here, we report a comprehensive NGS-based analysis of the M-CH mutational landscape at baseline and follow-up in patients enrolled in the Fondazione Italiana Linfomi (FIL) MCL0208 phase 3 trial (NCT02354313), evaluating lenalidomide maintenance versus observation after chemoimmunotherapy and autologous stem cell transplantation (ASCT) in untreated young MCL patients. Overall, 254/300 (85%) enrolled patients (median age 57 years [32-66]) had a baseline sample available for CH analysis.
View Article and Find Full Text PDFVet Dermatol
January 2025
Background: Chronic and recurrent pyoderma in dogs is driving a growing interest in natural antimicrobial products that offer minimal adverse effects and avoid antibiotic resistance.
Objectives: Evaluate the safety and efficacy of dermatological products with antimicrobial peptides and plant extracts, comparing them to chlorhexidine + miconazole and cephalexin therapy for superficial pyoderma in dogs.
Materials And Methods: Forty-five dogs with superficial pyoderma underwent clinical, cytopathological and microbiological diagnosis, and were randomly assigned to Group 1 (G1) treated with shampoo (two weekly baths) and lotion (twice daily on the affected areas) containing natural antimicrobials; Group 2 (G2) treated with two weekly baths using a therapeutic shampoo containing 2% chlorhexidine and 2.
Background: Pathogenic variants in may lead to a syndromic genetic aortopathy. Heritable thoracic aortic disease (HTAD) and arterial events may occur in -related disease but there are limited outcomes data on vascular events in this condition.
Methods: Clinical data, phenotypical features and aortic outcomes in individuals with pathogenic/likely pathogenic (P/LP) variants enrolled in the Montalcino Aortic Consortium registry were reviewed.
Objective: The primary goal of this article is to analyze whether there is still room for ovarian stimulation in poor responders prescribed the long protocol.
Methods: This retrospective cohort study analyzed the medical charts of patients seen at the Vida Centro de Fertilidade, a private fertility clinic in Rio de Janeiro, Brazil, from January 2018 to June 2023. It included poor responders described based on the Bologna criteria who were first prescribed conventional treatment with an antagonist protocol, without success, and then the long agonist protocol.